Thermo Fisher is a long time client of Panaxea. This resulted among others in a tailor made health economic model for the Procalcitonin (PCT) test manufactured by Thermo Fisher. Results of this model were published in the Journal of Medical Economics.

Recently, a new study was published by De Jong et al. in which new results of the PCT test were described. This article covered some of the economical aspects of adding a PCT to the current care. Because the economic analysis in the De Jong article was with a small perspective, we sent an comment to the Lancet Infectious Diseases , to emphasize that normally an economic analysis is broader than the one performed in the De Jong article. This, to ensure that people interested in the economic value of the PCT test, would see the full picture.

The comment can be found here.